Introduction: The Evolving Landscape of Community-Acquired Bacterial Pneumonia
Community-acquired bacterial pneumonia (CABP) remains a leading cause of morbidity and mortality worldwide, necessitating effective and versatile antimicrobial strategies. As antimicrobial resistance continues to challenge traditional therapy—including the rise of macrolide-resistant Streptococcus pneumoniae and concerns regarding the safety profile of fluoroquinolones—new therapeutic options are critical. Omadacycline, a first-in-class aminomethylcycline, was developed to overcome common mechanisms of tetracycline resistance, such as efflux and ribosomal protection. Following its initial FDA approval, the OPTIC-2 trial was conducted as a postmarketing regulatory commitment to further validate its efficacy and safety in a broader clinical context.
